TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)
Clinical trials for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may shrink Heart-Clogging protein in rare disease
Disease control OngoingThis study looks at whether the drug eplontersen can reduce abnormal protein buildup in the hearts of people with a rare condition called ATTR-CM. About 150 participants from a larger study will get heart scans after 140 weeks of treatment. The goal is to see if the drug clears t…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New drug shows promise for rare heart condition in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called eplontersen in people with ATTR-CM, a condition where abnormal proteins build up in the heart and cause it to weaken. About 1,400 adults who have already completed a related study or have a confirmed diagnosis will receive…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
Heart scans track protein buildup in rare disease
Knowledge-focused OngoingThis study uses MRI scans to measure amyloid protein buildup in the hearts of up to 150 people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Participants are already enrolled in a larger treatment study. The goal is to see how the amyloid burden changes over time,…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC